New insider activity at Incyte ( (INCY) ) has taken place on November 12, 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
In a significant financial move, Director Herve Hoppenot has sold a substantial portion of Incyte stock, totaling 187,500 shares. This transaction has garnered a noteworthy sum of $19,773,750, marking a pivotal moment in the company’s stock activity.
Recent Updates on INCY stock
Incyte Corporation has announced updates on several ongoing clinical studies, each with potential implications for its stock performance. The studies include a Phase 3 trial of ruxolitinib cream for hidradenitis suppurativa, which could provide a new topical treatment option and enhance market share in dermatology if successful. Another Phase 3 study focuses on ruxolitinib cream for pediatric nonsegmental vitiligo, aiming to restore skin pigmentation and potentially position Incyte favorably in pediatric dermatological care. Additionally, a study on INCB123667 is assessing pharmacokinetics and metabolite profiles, offering foundational data for drug development. A pivotal trial of povorcitinib targets prurigo nodularis, with success potentially boosting Incyte’s market position in dermatological treatments. Lastly, a Phase 3 study of axatilimab with corticosteroids for chronic graft-versus-host disease could establish Incyte as a leader in cGVHD treatment. Positive outcomes across these studies may enhance investor confidence and influence stock performance.
Spark’s Take on INCY Stock
According to Spark, TipRanks’ AI Analyst, INCY is a Outperform.
Incyte’s strong financial performance and positive earnings call sentiment are the primary drivers of its high score. The company’s robust profitability, minimal leverage, and strategic R&D investments position it well for future growth. Technical indicators suggest bullish momentum, although caution is advised due to overbought signals. The valuation is fair, supporting the company’s growth potential.
To see Spark’s full report on INCY stock, click here.
More about Incyte
YTD Price Performance: 55.56%
Average Trading Volume: 2,077,557
Technical Sentiment Signal: Buy
Current Market Cap: $20.81B